![The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients | BMC Cancer | Full Text The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-018-4987-0/MediaObjects/12885_2018_4987_Fig3_HTML.png)
The dynamic monitoring of CEA in response to chemotherapy and prognosis of mCRC patients | BMC Cancer | Full Text
![CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies | British Journal of Cancer CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies | British Journal of Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41416-021-01483-x/MediaObjects/41416_2021_1483_Fig3_HTML.png)
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies | British Journal of Cancer
![The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy - Annals of Oncology The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/d91b4cf4-dc6f-4cae-b1b9-6c9310a6b64b/gr1_lrg.jpg)
The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy - Annals of Oncology
![A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo | Science Translational Medicine A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo | Science Translational Medicine](https://www.science.org/cms/10.1126/scitranslmed.abm0306/asset/bb6cd38e-689c-4e12-8696-6f6055d0c8d5/assets/images/large/scitranslmed.abm0306-f2.jpg)
A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo | Science Translational Medicine
![Recombinant AAV-CEA Tumor Vaccine in Combination with an Immune Adjuvant Breaks Tolerance and Provides Protective Immunity: Molecular Therapy - Oncolytics Recombinant AAV-CEA Tumor Vaccine in Combination with an Immune Adjuvant Breaks Tolerance and Provides Protective Immunity: Molecular Therapy - Oncolytics](https://www.cell.com/cms/attachment/73f7efde-54bb-407d-a67c-473a16beb28d/gr1.jpg)
Recombinant AAV-CEA Tumor Vaccine in Combination with an Immune Adjuvant Breaks Tolerance and Provides Protective Immunity: Molecular Therapy - Oncolytics
![Impact of Different Selectivity between Soluble and Membrane-bound Forms of Carcinoembryonic Antigen (CEA) on the Target-mediated Disposition of Anti-CEA Monoclonal Antibodies | Drug Metabolism & Disposition Impact of Different Selectivity between Soluble and Membrane-bound Forms of Carcinoembryonic Antigen (CEA) on the Target-mediated Disposition of Anti-CEA Monoclonal Antibodies | Drug Metabolism & Disposition](https://dmd.aspetjournals.org/sites/default/files/highwire/dmd/47/11.cover-source.jpg)